nifedipine has been researched along with Benign Neoplasms in 25 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 1054 postmyocardial infarction patients were divided randomly into those being treated with calcium antagonists (n = 566 [nifedipine, 425 patients and diltiazem, 141 patients]) and controls (no calcium antagonist; n = 488)." | 9.09 | Incidence of cancer in postmyocardial infarction patients treated with short-acting nifedipine and diltiazem. Secondary Prevention Group. ( Ishikawa, K; Kanamasa, K; Kimura, A; Miyataka, M; Takenaka, T, 1999) |
| " The purpose of this study was to assess the risk ratio for cancer mortality associated with nifedipine in a large population of patients post-myocardial infarction." | 9.08 | Nifedipine and cancer mortality: ten-year follow-up of 2607 patients after acute myocardial infarction. ( Behar, S; Boyko, V; Goldbourt, U; Jonas, M; Mandelzweig, L; Reicher-Reiss, H, 1998) |
| " Reports on clinical use of bisphosphonates for bone pain in cancer, controlled release opioids, selection of laxatives for opioid-induced constipation and the calcium channel blocker nifedipine as an analgesic are described." | 8.81 | Analgesia issues in palliative care: bone pain, controlled release opioids, managing opioid-induced constipation and nifedipine as an analgesic. ( Fine, PG, 2002) |
| "To compare the clinical efficacy and safety of sublingual nifedipine and intravenous urapidil in the treatment of acute postoperative hypertension." | 7.77 | [Efficacy of sublingual nifedipine and intravenous urapidil for treatment of acute postoperative hypertension]. ( Lou, N; Wang, DF; Wang, Z, 2011) |
| "A total of 1054 postmyocardial infarction patients were divided randomly into those being treated with calcium antagonists (n = 566 [nifedipine, 425 patients and diltiazem, 141 patients]) and controls (no calcium antagonist; n = 488)." | 5.09 | Incidence of cancer in postmyocardial infarction patients treated with short-acting nifedipine and diltiazem. Secondary Prevention Group. ( Ishikawa, K; Kanamasa, K; Kimura, A; Miyataka, M; Takenaka, T, 1999) |
| " The purpose of this study was to assess the risk ratio for cancer mortality associated with nifedipine in a large population of patients post-myocardial infarction." | 5.08 | Nifedipine and cancer mortality: ten-year follow-up of 2607 patients after acute myocardial infarction. ( Behar, S; Boyko, V; Goldbourt, U; Jonas, M; Mandelzweig, L; Reicher-Reiss, H, 1998) |
| " Reports on clinical use of bisphosphonates for bone pain in cancer, controlled release opioids, selection of laxatives for opioid-induced constipation and the calcium channel blocker nifedipine as an analgesic are described." | 4.81 | Analgesia issues in palliative care: bone pain, controlled release opioids, managing opioid-induced constipation and nifedipine as an analgesic. ( Fine, PG, 2002) |
| "To compare the clinical efficacy and safety of sublingual nifedipine and intravenous urapidil in the treatment of acute postoperative hypertension." | 3.77 | [Efficacy of sublingual nifedipine and intravenous urapidil for treatment of acute postoperative hypertension]. ( Lou, N; Wang, DF; Wang, Z, 2011) |
| "Apatinib is a small-molecule tyrosine kinase inhibitor for the treatment of recurrent or progressive advanced-stage gastric adenocarcinoma or gastroesophageal junction cancer." | 2.94 | Effects of Apatinib on the Pharmacokinetics of Nifedipine and Warfarin in Patients with Advanced Solid Tumors. ( Chen, XY; Guo, LX; Li, W; Liu, YP; Mao, SY; Qu, XJ; Teng, Z; Wang, QR; Zhang, YF; Zhong, DF; Zhu, YT, 2020) |
| "Etoposide was administered intravenously on day 2 in a dose of 150-250 mg m-2 and orally 150-300 mg twice daily on days 3 and 4." | 2.67 | A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. ( Carmichael, J; Dolega-Ossowski, E; Harris, AL; Idle, JR; Joel, S; Monkman, SC; Philip, PA; Tonkin, K, 1992) |
| " These differences can be attributed at least in part to the low catecholamine profile of verapamil and the marked rapid adrenergic activation with short-acting nifedipine, which could also explain the adverse effects found when this agent is given to patients with acute coronary syndromes." | 2.40 | Calcium channel blockers for hypertension: dissecting the evidence for adverse effects. ( Opie, LH, 1997) |
| " The interpretation of the results of these studies and their application to clinical practice requires an understanding of study design constraints, conflicting results and limitations in extrapolating study findings to other dosage strengths, formulations or agents within the calcium channel antagonist class." | 2.40 | Calcium channel antagonists: morbidity and mortality--what's the evidence? ( Parra, D; Straka, RJ; Swanson, AL, 1998) |
| "Cardiovascular and cancer illnesses often co-exist, share pathological pathways, and complicate therapy." | 1.72 | Calcium-channel-blockers exhibit divergent regulation of cancer extravasation through the mechanical properties of cancer cells and underlying vascular endothelial cells. ( Bajpai, SK; Edwina, P; Roy, B; Sivasubramaniapandian, M; Vaibavi, SR; Vaippully, R, 2022) |
| "Finally, tested in a panel of cancer cells, the water-soluble form of 3a, compound 8, displayed antiproliferative effects in the range of 8-35 μM and increased H4K16 deacetylation, suggesting a possible role for SIRT1 activators in cancer therapy." | 1.43 | 1,4-Dihydropyridines Active on the SIRT1/AMPK Pathway Ameliorate Skin Repair and Mitochondrial Function and Exhibit Inhibition of Proliferation in Cancer Cells. ( Altucci, L; Atlante, S; Budriesi, R; Carafa, V; Carnevale, I; Cencioni, C; Del Bufalo, D; Gabellini, C; Gaetano, C; Mai, A; Mellini, P; Moniot, S; Nebbioso, A; Polletta, L; Saladini, S; Spallotta, F; Steegborn, C; Tafani, M; Tardugno, M; Trisciuoglio, D; Valente, S; Zwergel, C, 2016) |
| "Fourteen human cancer cell lines with and without DNA MMR derived from carcinomas of the colon, bladder, ovary and prostate were treated with CAI, vehicle or control drugs (nifedipine and 5-flurouracil)." | 1.35 | Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency. ( Friedlander, ML; Kohn, EC; Qu, XJ; Yang, JL; Yu, Y, 2008) |
| "Nifedipine-treated cells also showed a decrease in cytosolic cytochrome c release and a decrease in caspase 3 activation, compared to cells treated only with Rec-1 antibody." | 1.33 | Anti-recoverin antibodies induce an increase in intracellular calcium, leading to apoptosis in retinal cells. ( Adamus, G; Duvoisin, RM; Shiraga, S; Webb, S, 2006) |
| "Of 246 incident cancer cases, 129 occurred among the users (2." | 1.30 | Calcium channel blocking agents and risk of cancer in patients with coronary heart disease. Benzafibrate Infarction Prevention (BIP) Study Research Group. ( Behar, S; Boyko, V; Braun, S; Goldbourt, U; Kaplinsky, E; Laniado, S; Reicher-Reiss, H, 1998) |
| " Pharmacokinetic data were analyzed by a nonlinear weighted least-square regression program (SAS-NLIN)." | 1.28 | Pharmacokinetics of vincristine in cancer patients treated with nifedipine. ( Aristei, C; Boschetti, E; Colozza, M; Del Favero, A; Fedeli, L; Guerciolini, R; Rambotti, P; Rossetti, R; Sabalich, I; Tonato, M, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.00) | 18.7374 |
| 1990's | 9 (36.00) | 18.2507 |
| 2000's | 7 (28.00) | 29.6817 |
| 2010's | 3 (12.00) | 24.3611 |
| 2020's | 4 (16.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Valente, S | 1 |
| Mellini, P | 1 |
| Spallotta, F | 1 |
| Carafa, V | 1 |
| Nebbioso, A | 1 |
| Polletta, L | 1 |
| Carnevale, I | 1 |
| Saladini, S | 1 |
| Trisciuoglio, D | 1 |
| Gabellini, C | 1 |
| Tardugno, M | 1 |
| Zwergel, C | 1 |
| Cencioni, C | 1 |
| Atlante, S | 1 |
| Moniot, S | 1 |
| Steegborn, C | 1 |
| Budriesi, R | 1 |
| Tafani, M | 1 |
| Del Bufalo, D | 1 |
| Altucci, L | 1 |
| Gaetano, C | 1 |
| Mai, A | 1 |
| Zhao, Y | 1 |
| Guan, YY | 1 |
| Zhao, F | 1 |
| Yu, T | 1 |
| Zhang, SJ | 1 |
| Zhang, YZ | 1 |
| Duan, YC | 1 |
| Zhou, XL | 1 |
| Vaibavi, SR | 1 |
| Sivasubramaniapandian, M | 1 |
| Vaippully, R | 1 |
| Edwina, P | 1 |
| Roy, B | 1 |
| Bajpai, SK | 1 |
| Tchernev, G | 1 |
| Zhu, YT | 1 |
| Teng, Z | 1 |
| Zhang, YF | 1 |
| Li, W | 1 |
| Guo, LX | 1 |
| Liu, YP | 1 |
| Qu, XJ | 2 |
| Wang, QR | 1 |
| Mao, SY | 1 |
| Chen, XY | 1 |
| Zhong, DF | 1 |
| Oguro, H | 1 |
| Saito, Y | 1 |
| Franklin, PH | 1 |
| Banfor, PN | 1 |
| Tapang, P | 1 |
| Segreti, JA | 1 |
| Widomski, DL | 1 |
| Larson, KJ | 1 |
| Noonan, WT | 1 |
| Gintant, GA | 1 |
| Davidsen, SK | 1 |
| Albert, DH | 1 |
| Fryer, RM | 1 |
| Cox, BF | 1 |
| Wang, Z | 1 |
| Wang, DF | 1 |
| Lou, N | 1 |
| Fine, PG | 1 |
| Adamus, G | 1 |
| Webb, S | 1 |
| Shiraga, S | 1 |
| Duvoisin, RM | 1 |
| Gould, S | 1 |
| Westwood, FR | 1 |
| Curwen, JO | 1 |
| Ashton, SE | 1 |
| Roberts, DW | 1 |
| Lovick, SC | 1 |
| Ryan, AJ | 1 |
| Yang, JL | 1 |
| Yu, Y | 1 |
| Kohn, EC | 1 |
| Friedlander, ML | 1 |
| Bates, SE | 1 |
| Regis, JI | 1 |
| Robey, RW | 1 |
| Zhan, Z | 1 |
| Scala, S | 1 |
| Meadows, BJ | 1 |
| Messerli, FH | 1 |
| Davis, WB | 1 |
| Wells, SR | 1 |
| Kuller, JA | 1 |
| Thorp, JM | 1 |
| Opie, LH | 1 |
| Braun, S | 1 |
| Boyko, V | 2 |
| Behar, S | 2 |
| Reicher-Reiss, H | 2 |
| Laniado, S | 1 |
| Kaplinsky, E | 1 |
| Goldbourt, U | 2 |
| Straka, RJ | 1 |
| Swanson, AL | 1 |
| Parra, D | 1 |
| Jonas, M | 1 |
| Mandelzweig, L | 1 |
| Kanamasa, K | 1 |
| Kimura, A | 1 |
| Miyataka, M | 1 |
| Takenaka, T | 1 |
| Ishikawa, K | 1 |
| Philip, PA | 1 |
| Joel, S | 1 |
| Monkman, SC | 1 |
| Dolega-Ossowski, E | 1 |
| Tonkin, K | 1 |
| Carmichael, J | 1 |
| Idle, JR | 1 |
| Harris, AL | 1 |
| Fedeli, L | 1 |
| Colozza, M | 1 |
| Boschetti, E | 1 |
| Sabalich, I | 1 |
| Aristei, C | 1 |
| Guerciolini, R | 1 |
| Del Favero, A | 1 |
| Rossetti, R | 1 |
| Tonato, M | 1 |
| Rambotti, P | 1 |
| Lundberg, JM | 1 |
| Torssell, L | 1 |
| Sollevi, A | 1 |
| Pernow, J | 1 |
| Theodorsson Norheim, E | 1 |
| Anggård, A | 1 |
| Hamberger, B | 1 |
9 reviews available for nifedipine and Benign Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
Topics: Ectoderm; Enhancer of Zeste Homolog 2 Protein; Humans; Intercellular Signaling Peptides and Proteins | 2022 |
[Paraneoplastic retinopathy].
Topics: Antibodies, Neoplasm; Autoantibodies; Calcium Channel Blockers; HSC70 Heat-Shock Proteins; Humans; N | 2008 |
Analgesia issues in palliative care: bone pain, controlled release opioids, managing opioid-induced constipation and nifedipine as an analgesic.
Topics: Adult; Analgesics; Analgesics, Opioid; Bone and Bones; Calcium Channel Blockers; Cathartics; Constip | 2002 |
Chemoresistance in the clinic: overview 1994.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Dipyridamole; Drug Resistance | 1994 |
Safety of calcium antagonists: dissecting the evidence.
Topics: Calcium Channel Blockers; Clinical Trials as Topic; Gastrointestinal Hemorrhage; Humans; Myocardial | 1996 |
Analysis of the risks associated with calcium channel blockade: implications for the obstetrician-gynecologist.
Topics: Calcium Channel Blockers; Drug Interactions; Female; Gastrointestinal Hemorrhage; Heart Diseases; Hu | 1997 |
Calcium channel blockers for hypertension: dissecting the evidence for adverse effects.
Topics: Calcium Channel Blockers; Catecholamines; Cerebrovascular Disorders; Drug Evaluation; Gastrointestin | 1997 |
Calcium channel antagonists: morbidity and mortality--what's the evidence?
Topics: Administration, Sublingual; Aged; Calcium Channel Blockers; Gastrointestinal Hemorrhage; Humans; Hyp | 1998 |
5 trials available for nifedipine and Benign Neoplasms
| Article | Year |
|---|---|
Effects of Apatinib on the Pharmacokinetics of Nifedipine and Warfarin in Patients with Advanced Solid Tumors.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cyto | 2020 |
Chemoresistance in the clinic: overview 1994.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Dipyridamole; Drug Resistance | 1994 |
Nifedipine and cancer mortality: ten-year follow-up of 2607 patients after acute myocardial infarction.
Topics: Aged; Calcium Channel Blockers; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; | 1998 |
Incidence of cancer in postmyocardial infarction patients treated with short-acting nifedipine and diltiazem. Secondary Prevention Group.
Topics: Calcium Channel Blockers; Cause of Death; Diltiazem; Female; Humans; Male; Middle Aged; Myocardial I | 1999 |
A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide.
Topics: Administration, Oral; Adult; Aged; Drug Administration Schedule; Drug Evaluation; Drug Interactions; | 1992 |
12 other studies available for nifedipine and Benign Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
1,4-Dihydropyridines Active on the SIRT1/AMPK Pathway Ameliorate Skin Repair and Mitochondrial Function and Exhibit Inhibition of Proliferation in Cancer Cells.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cell Pro | 2016 |
Calcium-channel-blockers exhibit divergent regulation of cancer extravasation through the mechanical properties of cancer cells and underlying vascular endothelial cells.
Topics: Calcium; Calcium Channel Blockers; Diltiazem; Endothelial Cells; Neoplasms; Nifedipine; Verapamil | 2022 |
NITROSAMINE CONTAMINATION WITHIN CARDIAC MULTIMEDICATION - SARTANS (VALSARTAN), CALCIUM CHANNEL BLOCKERS (AMLODIPINE AND NIFEDIPINE), AND ANTIARRHYTHMICS (PROPAFENONE) AS A SIGNIFICANT FACTOR IN THE DEVELOPMENT AND PROGRESSION OF MULTIPLE KERATINOCYTIC CA
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Calcium Channel Blocker | 2023 |
Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growt
Topics: Acrylates; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; A | 2009 |
[Efficacy of sublingual nifedipine and intravenous urapidil for treatment of acute postoperative hypertension].
Topics: Administration, Sublingual; Aged; Antihypertensive Agents; Female; Humans; Hypertension; Injections, | 2011 |
Anti-recoverin antibodies induce an increase in intracellular calcium, leading to apoptosis in retinal cells.
Topics: Animals; Antibodies, Monoclonal; Apoptosis; Autoantibodies; bcl-2-Associated X Protein; bcl-X Protei | 2006 |
Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Antineoplasti | 2007 |
Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency.
Topics: Antineoplastic Agents; Apoptosis; Calcium Channel Blockers; Cell Cycle; Cell Line, Tumor; Chromosome | 2008 |
Calcium channel blocking agents and risk of cancer in patients with coronary heart disease. Benzafibrate Infarction Prevention (BIP) Study Research Group.
Topics: Aged; Calcium Channel Blockers; Cause of Death; Confidence Intervals; Coronary Disease; Diltiazem; F | 1998 |
Pharmacokinetics of vincristine in cancer patients treated with nifedipine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Chemical Analysis; Female; Humans; Male; | 1989 |
Neuropeptide Y and sympathetic vascular control in man.
Topics: Adult; Animals; Arteries; Blood Pressure; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Chrom | 1985 |